Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Hanneke W. Wilmink

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6686-2904; OpenAlex author ID A5015859868. Sources: ClinicalTrials.gov.

Their work

Papers
13
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
95
Papers, trials and grants by year

2009: 1 trial · 2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 2 papers

Papers 13

  1. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  2. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  3. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  4. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  5. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  6. Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study. Co-author DOI 10.1016/j.jtha.2023.06.009↗
  7. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… Co-author DOI 10.1002/jso.26567↗
  8. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-… Co-author DOI 10.1097/sla.0000000000005120↗
  9. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  10. Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classificati… Co-author DOI 10.1038/s41598-019-56826-9↗
  11. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  12. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Co-author DOI 10.1038/s41389-018-0096-9↗
  13. Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. Co-author DOI 10.1016/j.ejca.2016.01.001↗

Trials 2

  1. Metformin Combined With Chemotherapy for Pancreatic Cancer Principal investigator NCT01210911↗
  2. Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer Principal investigator NCT01077986↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 11 shared papers, 2016–2026 · strength 1.40
  2. Izaak Quintus Molenaar · 6 shared papers, 2016–2026 · strength 0.78
  3. Lodewijk A.A. Brosens · 4 shared papers, 2025–2026 · strength 0.74
  4. Lois A. Daamen · 5 shared papers, 2021–2026 · strength 0.74
  5. Hjalmar C. van Santvoort · 5 shared papers, 2021–2026 · strength 0.74
  6. Ignace H. J. T. de Hingh · 5 shared papers, 2016–2026 · strength 0.59
  7. Hanneke W.M. van Laarhoven · 5 shared papers, 2016–2026 · strength 0.57
  8. Gijs A. Patijn · 4 shared papers, 2021–2026 · strength 0.56
  9. Vincent Erwin de Meijer · 4 shared papers, 2021–2026 · strength 0.56
  10. Martijn W.J. Stommel · 4 shared papers, 2021–2026 · strength 0.56
  11. Maarten F. Bijlsma · 4 shared papers, 2018–2026 · strength 0.51
  12. Casper H.J. van Eijck · 3 shared papers, 2021–2026 · strength 0.47
  13. Bas Groot Koerkamp · 3 shared papers, 2021–2026 · strength 0.44
  14. Jeanin Elise van Hooft · 2 shared papers, 2026 · strength 0.38
  15. Lydia G. van der Geest · 2 shared papers, 2026 · strength 0.38
  16. J. Sven D. Mieog · 2 shared papers, 2025 · strength 0.36
  17. Sebastiaan Festen · 3 shared papers, 2021–2025 · strength 0.36
  18. Geert Kazemier M · 2 shared papers, 2025–2026 · strength 0.35
  19. Nick van Es · 2 shared papers, 2023–2025 · strength 0.34
  20. Floris T.M. Bosch · 2 shared papers, 2023–2025 · strength 0.34
  21. Frederike Dijk · 3 shared papers, 2018–2025 · strength 0.33
  22. Joanne Verheij · 2 shared papers, 2020–2025 · strength 0.27
  23. Pauline A. J. Vissers · 1 shared paper, 2026 · strength 0.20
  24. Jeroen T. Buijs · 1 shared paper, 2025 · strength 0.19
  25. Svein Olav Bratlie · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.